Navigation Links
Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned

Additional beneficial effects on cardiometabolic risk factors beyond those expected from weight loss in trials of the anti-obesity drug rimonabant may not be due to the drug itself, reports an article in the June issue of Drug and Therapeutics Bulletin (DTB).

Advertisements for rimonabant (sold under the brand name Acomplia by Sanofi-Aventis) claim that an estimated 50% of the effects on cardiometabolic risk factors are beyond those expected from weight loss alone. But DTB argues that these effects are not proven to be due to the drug itself.

Also, no published trials have compared rimonabant with either of the other anti-obesity drugs orlistat or sibutramine. Instead, rimonobants effects on weight have been assessed in four double-blind trials comparing the drug with placebo.

The article says: In three of the trial reports, the authors state that the effects of rimonabant on HDL, triglycerides and HBA1c were partly independent of weight loss. However, it is not proven that any independent effect is wholly or partially attributable to rimonabant.

The article suggests that these observed effects might be related to increased activity based on the lifestyle advice given to participants at the start of the trials.

Furthermore, it is not known whether rimonabants effects on individual risk factors translate into a reduced long-term likelihood of cardiovascular events, the article adds.

. Rimonabant has not been directly compared with other, less expensive, drug treatments for obesity. Orlistat is the drug for obesity for which there is the most evidence for efficacy and safety to date, and we have previously concluded that it is a reasonable option for obese patients where diet and exercise and/or behavioural measures alone have failed.

Rimonabant is the most expensive of the anti-obesity drugs. A years treatment with rimonabant 20mg daily costs the NHS around 720, compar ed with 520 for orlistat 120 mg three times daily and 480-570 for sibutramine 10-15 mg daily.


'"/>




Related medicine news :

1. Anti-obesity drugs for FDA approval
2. Canada Confronts Obesity Head-on, Anti-obesity Campaign on Fast Track
3. Lean Protein Could Be Key to Obesity Drugs
4. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
5. Nasal Spray Could Take Drugs Direct to Brain.
6. Emphasis to ban Drugs ads by Doctors
7. Osteoporosis Drugs: right time to take-off
8. Drugs disrupt formation of blood vessels
9. Drugs to stop burgeon of HIV
10. Misleading Advertisements for Prescription Drugs
11. Drugs For Anthrax May Interfere With Oral Contraceptives
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/24/2017)... ... January 23, 2017 , ... The TouchPoint Solution, ... who entered metrics into the product’s app. The data replicates and validates ... that within just 30 seconds of using Buzzies, people experienced a 74 percent ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... a new plugin that allows sleep centers to automatically connect and initialize all ... a thin client browser plugin is quickly installed on first use and then ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... week at a new domain address. Alpine Springs Rehabilitation & Recovery Center’s new ... debuted a new logo along with its redesigned and retooled website. The treatment ...
(Date:1/23/2017)... Palo Alto, CA (PRWEB) , ... ... ... Translations, a provider of translation and localization services for life science companies, ... testing and inspection organization, TÜV SÜD America. ISO 17100 is the globally ...
(Date:1/23/2017)... ... January 23, 2017 , ... DMG ... Innovations with Ed Begley, Jr., scheduled to broadcast Saturday, January 28, 2017 at ... was founded in 2008 to address the limitations of fatigue monitoring technologies within ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 23, 2017  Allergan plc, (NYSE: AGN ), ... of the International Headache Academy (IHA). Designed to inspire a ... scientists, IHA offers a three-day, intensive overview on research and ... been the sole sponsor since the inception of IHA in ... in Europe in 2014. ...
(Date:1/23/2017)...  Using Astute Medical,s NephroCheck Test ... kidney injury (AKI) after open-heart surgery and providing ... significantly improved outcomes by reducing the occurrence ... percent, according to a study published ... Medicine. Experience the interactive Multimedia ...
(Date:1/23/2017)... YORK , January 23, 2017 ... Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX ), Sophiris Bio ... MNTA ), and Agile Therapeutics Inc. (NASDAQ: ... sector which turned somewhat lower in late trade on Friday, ... Index dropping about 0.3%, while shares of health care companies ...
Breaking Medicine Technology: